Ascendis Pharma A/S
- Tickers
- ASND
- Headquarters
- Not recorded
- SEC CIK
- 0001612042
- Website
- Not recorded
Closing prices
Latest close, 253.00
| Date | Close |
|---|---|
| 200.98 | |
| 208.24 | |
| 197.75 | |
| 199.28 | |
| 197.74 | |
| 196.01 | |
| 201.16 | |
| 199.22 | |
| 206.45 | |
| 204.40 | |
| 216.56 | |
| 217.13 | |
| 212.15 | |
| 209.55 | |
| 210.49 | |
| 209.03 | |
| 206.65 | |
| 210.01 | |
| 212.33 | |
| 210.85 | |
| 202.16 | |
| 200.50 | |
| 208.58 | |
| 205.44 | |
| 207.12 | |
| 196.63 | |
| 201.24 | |
| 210.16 | |
| 220.42 | |
| 213.24 | |
| 212.11 | |
| 202.82 | |
| 199.80 | |
| 199.99 | |
| 209.43 | |
| 209.23 | |
| 212.81 | |
| 208.98 | |
| 211.02 | |
| 209.34 | |
| 213.24 | |
| 213.29 | |
| 213.15 | |
| 209.29 | |
| 213.28 | |
| 208.75 | |
| 202.99 | |
| 208.76 | |
| 215.05 | |
| 217.32 | |
| 215.04 | |
| 205.83 | |
| 215.58 | |
| 216.66 | |
| 228.65 | |
| 235.39 | |
| 233.65 | |
| 238.80 | |
| 222.45 | |
| 223.95 | |
| 226.10 | |
| 223.59 | |
| 224.67 | |
| 219.73 | |
| 217.38 | |
| 222.15 | |
| 222.03 | |
| 224.19 | |
| 221.49 | |
| 218.10 | |
| 216.32 | |
| 223.41 | |
| 226.83 | |
| 230.21 | |
| 225.00 | |
| 234.95 | |
| 234.99 | |
| 228.00 | |
| 228.99 | |
| 233.50 | |
| 242.09 | |
| 239.22 | |
| 241.38 | |
| 237.35 | |
| 240.65 | |
| 239.92 | |
| 240.52 | |
| 227.50 | |
| 229.01 | |
| 225.98 | |
| 231.03 | |
| 228.06 | |
| 227.41 | |
| 223.82 | |
| 221.88 | |
| 218.06 | |
| 215.54 | |
| 220.90 | |
| 220.60 | |
| 216.95 | |
| 218.35 | |
| 228.73 | |
| 228.24 | |
| 229.25 | |
| 226.69 | |
| 220.48 | |
| 233.20 | |
| 241.71 | |
| 239.28 | |
| 248.55 | |
| 249.84 | |
| 241.71 | |
| 242.95 | |
| 244.48 | |
| 245.38 | |
| 240.29 | |
| 231.05 | |
| 225.00 | |
| 229.27 | |
| 226.66 | |
| 222.08 | |
| 220.28 | |
| 229.38 | |
| 220.93 | |
| 228.71 | |
| 225.28 | |
| 235.90 | |
| 246.14 | |
| 238.66 | |
| 238.67 | |
| 237.65 | |
| 243.58 | |
| 245.49 | |
| 240.50 | |
| 237.64 | |
| 237.98 | |
| 241.34 | |
| 247.51 | |
| 247.05 | |
| 239.65 | |
| 235.26 | |
| 237.47 | |
| 224.11 | |
| 218.82 | |
| 216.60 | |
| 216.79 | |
| 218.84 | |
| 210.45 | |
| 205.81 | |
| 213.23 | |
| 209.79 | |
| 215.60 | |
| 218.06 | |
| 223.29 | |
| 231.20 | |
| 231.15 | |
| 230.83 | |
| 228.00 | |
| 238.59 | |
| 238.01 | |
| 261.58 | |
| 260.75 | |
| 263.70 | |
| 266.72 | |
| 267.79 | |
| 274.50 | |
| 267.92 | |
| 266.97 | |
| 277.18 | |
| 275.43 | |
| 270.45 | |
| 265.22 | |
| 265.57 | |
| 268.57 | |
| 259.80 | |
| 261.00 | |
| 251.76 | |
| 255.20 | |
| 251.93 | |
| 252.66 | |
| 253.86 | |
| 253.42 | |
| 254.44 | |
| 252.05 | |
| 251.07 | |
| 243.91 | |
| 243.45 | |
| 244.59 | |
| 244.20 | |
| 249.85 | |
| 255.41 | |
| 255.62 | |
| 254.57 | |
| 255.46 | |
| 246.23 | |
| 248.50 | |
| 247.40 | |
| 248.85 | |
| 259.62 | |
| 254.81 | |
| 253.29 | |
| 251.95 | |
| 252.99 | |
| 250.25 | |
| 249.36 | |
| 247.91 | |
| 263.04 | |
| 260.25 | |
| 267.31 | |
| 271.12 | |
| 270.56 | |
| 270.09 | |
| 260.81 | |
| 261.23 | |
| 263.52 | |
| 264.92 | |
| 239.77 | |
| 247.69 | |
| 239.04 | |
| 236.72 | |
| 237.59 | |
| 237.57 | |
| 223.13 | |
| 230.70 | |
| 225.60 | |
| 230.05 | |
| 228.07 | |
| 227.83 | |
| 227.31 | |
| 227.87 | |
| 228.03 | |
| 226.05 | |
| 228.41 | |
| 222.69 | |
| 229.23 | |
| 227.00 | |
| 223.21 | |
| 227.00 | |
| 226.62 | |
| 225.25 | |
| 229.95 | |
| 234.33 | |
| 238.90 | |
| 242.99 | |
| 243.37 | |
| 245.15 | |
| 245.85 | |
| 249.55 | |
| 253.00 |
Drugs
| Drug | Indications | Phase | Next catalyst | CT-VCA | Trials |
|---|---|---|---|---|---|
| Navepegritide | Not recorded | Approved | None scheduled | 0 |
FDA-approved applications
| Application | Brand names | Active ingredients | First approved | Status |
|---|---|---|---|---|
| NDA 219164 | YUVIWEL | NAVEPEGRITIDE | Prescription |
Open in the approved-drug database for Ascendis Pharma A/S
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | 720,132,000 EUR | 1 Jan 2025 to 31 Dec 2025 FY2025 | 20-F for Revenue on sec.gov (opens in a new tab)Filed |
| Net income (loss) | −228,034,000 EUR | 1 Jan 2025 to 31 Dec 2025 FY2025 | 20-F for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 303,621,000 EUR | 1 Jan 2025 to 31 Dec 2025 FY2025 | 20-F for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | Not reported in XBRL filings since 2015 | ||
| Cash and cash equivalents | 616,041,000 EUR | At 31 Dec 2025 FY2025 | 20-F for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | Not reported in XBRL filings since 2015 | ||
| Total liabilities | 1,465,391,000 EUR | At 31 Dec 2025 FY2025 | 20-F for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | −162,821,000 EUR | At 31 Dec 2025 FY2025 | 20-F for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 61,977,408 shares | At 31 Dec 2025 FY2025 | 20-F for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Jan 2025 to 31 Dec 2025 FY2025 | 720,132,000 EUR | 20-F filed 11 Feb 2026 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2025 to 30 Sep 2025 FY2025 Q3 | 213,634,000 EUR | 6-K filed 12 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2025 to 30 Jun 2025 FY2025 Q2 | 158,045,000 EUR | 6-K filed 7 Aug 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2025 to 31 Mar 2025 FY2025 Q1 | 100,954,000 EUR | 6-K filed 1 May 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2024 to 31 Dec 2024 FY2025 | 363,641,000 EUR | 20-F filed 11 Feb 2026 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2024 to 30 Sep 2024 FY2025 Q3 | 57,833,000 EUR | 6-K filed 12 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2024 to 30 Jun 2024 FY2025 Q2 | 35,998,000 EUR | 6-K filed 7 Aug 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2024 to 31 Mar 2024 FY2025 Q1 | 95,894,000 EUR | 6-K filed 1 May 2025 on sec.gov (opens in a new tab)Filed |
The newest 12 periods of each metric are listed; older ones are on sec.gov.
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-29 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for Ascendis Pharma A/S on Insider TradesLast 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).
- Buys code P
- 2 transactions, 2,000 shares, $492,654
- Sells code S
- 2 transactions, 3,236 shares, $872,904.68
- Other all other codes
- 1 transaction: grants, exercises, tax withholding, gifts and similar
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.